Abstract
Purpose
[123I]FP-CIT SPECT is a valuable diagnostic tool to discriminate Lewy body dementia from Alzheimer’s dementia. To date, however, it is uncertain whether the frequently used acetylcholinesterase inhibitors (AChEIs) by demented patients, have an effect on [123I]FP-CIT binding to dopamine transporters (DATs). Earlier animal studies showed a decline of DAT availability after acute intravenous injection of AChEIs. The aim of this study was to investigate effects of single intravenous, single oral and subchronic oral administration of AChEIs on DAT availability in the rat brain as measured by [123I]FP-CIT.
Methods
Biodistribution studies were performed in Wistar rats (n = 5–16 per group). Before [123I]FP-CIT injection, rats were injected intravenously with a single dose of the AChEI rivastigmine (2.5 mg/kg body weight) or donepezil (0.5 mg/kg), the DAT-blocker methylphenidate (10 mg/kg) or saline. A second group was orally treated with a single dose of rivastigmine or donepezil (2.5 mg/kg), methylphenidate (10 mg/kg) or saline before injection of [123I]FP-CIT. Studies were also performed in rats that were orally treated during 14 consecutive days with either rivastigmine (1 mg/kg daily), donepezil (1.5 mg/kg daily), methylphenidate (2.5 mg/kg) or saline. Brain parts were assayed in a gamma counter, and specific striatum/cerebellum ratios were calculated for the [123I]FP-CIT binding to DATs.
Results
No significant effects of either single intravenous, single oral or subchronic oral administration of AChEIs on striatal FP-CIT binding could be detected. Single pretreatment with methylphenidate resulted in an expected significantly lower striatal FP-CIT binding.
Conclusion
We conclude that in rats, single intravenous and single or subchronic oral administration of the tested AChEIs does not lead to an important alteration of [123I]FP-CIT binding to striatal DATs. Therefore, it is unlikely that these drugs will induce large effects on the interpretation of [123I]FP-CIT SPECT scans in routine clinical studies.
Similar content being viewed by others
References
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:133–40.
Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134–40.
McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–6.
Kilbourn MR, Kemmerer ES, Desmond TJ, Sherman PS, Frey KA. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain. Exp Neurol 2004;188:387–90.
Tsukada H, Nishiyama S, Ohba H, Sato K, Harada N, Kakiuchi T. Cholinergic neuronal modulations affect striatal dopamine transporter activity: PET studies in the conscious monkey brain. Synapse 2001;42:193–5.
Taylor JP, Colloby SJ, McKeith IG, Burn DJ, Williams D, Patterson J, et al. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer’s disease from dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2007;78:1069–71.
Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer’s disease, on cholinesterase activity in rats. Eur J Pharmacol 2000;389:173–9.
Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur J Pharmacol 2001;415:157–64.
Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, et al. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000;295:51–7.
Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999;380:101–7.
Enz A, Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004;47:408–13.
Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 2002;109:1067–80.
Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002;22:7264–71.
Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183–90.
Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 1997;25:345–9.
Lazartigues E, Freslon JL, Tellioglu T, Brefel-Courbon C, Pelat M, Tran MA, et al. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur J Pharmacol 1998;361:61–71.
Dronfield S, Egan K, Marsden CA, Green AR. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 2000;14:275–9.
Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos 1999;27:1406–14.
Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol 1999;373:187–93.
Gorentla BK, Vaughan RA. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuropharmacology 2005;49:759–68.
Acknowledgements
The authors wish to thank Vic Pinas for assistance in preparing the intravenous medication, Rianne Schmitz for assistance in the biodistribution experiments and Rob Kuiper for pharmacological advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knol, R.J.J., de Bruin, K., van Eck-Smit, B.L.F. et al. No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats. Eur J Nucl Med Mol Imaging 35, 598–604 (2008). https://doi.org/10.1007/s00259-007-0620-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-007-0620-1